This shows you the differences between two versions of the page.
mm:parameters:lipids:pe [2013/08/05 18:00] joaocoimbra removed |
— (current) | ||
---|---|---|---|
Line 1: | Line 1: | ||
- | ====== Phosphatidylethanolamines (PE) ====== | ||
- | For each phospholipid, its name, 4-letter code, composition of aliphatic chains (sn<sub>1</sub>/sn<sub>2</sub>), and parameter files are presented. In addition, the values for volume per lipid (V<sub>L</sub>), area per lipid (A<sub>L</sub>), and bilayer thickness (D<sub>HH</sub>) in a bilayer setting are given, together with experimental data (when available). These parameters were obtained under the General Amber Force Field (GAFF) terminology and general parameters. | ||
- | |||
- | |||
- | ---- | ||
- | |||
- | |||
- | ==== DLPE ==== | ||
- | |||
- | //1,2-dilauroyl-sn-glycero-3-phosphoethanolamine// | ||
- | |||
- | | {{ mm:parameters:lipids:dlpe.png?70 }} | Name | //1,2-dilauroyl-sn-glycero-3-phosphoethanolamine// ||| | ||
- | | ::: | 4-Letter code | DLPE ||| | ||
- | | ::: | sn<sub>1</sub>-sn<sub>2</sub> | 12:0/12:0 ||| | ||
- | | ::: | parameters | {{ mm:parameters:lipids:dle_frcmod.zip | frcmod }} {{ mm:parameters:lipids:dle_prepc.zip | prepc }} || [[#references | [Coimbra, 2013]]] | | ||
- | | ::: | **Validation** |||| | ||
- | | ::: | //Value// | //MD ± σ / Å// | //Experimental / Å// | //Reference// | | ||
- | | ::: | //V<sub>L</sub>// | 854 ± 2 | 907, 863 | [[http://www.ncbi.nlm.nih.gov/pubmed/11063882|Nagle, 2000]] \\ [[http://www.ncbi.nlm.nih.gov/pubmed/3768325|McIntosh, 1986]] | | ||
- | | ::: | //A<sub>L</sub>// | 40 ± 0.4 | 51.2, 41.0 | ::: | | ||
- | | ::: | //D<sub>HH</sub>// | 40 ± 0.1 | 35.6, 33.0, 39.8 | ::: | | ||
- | |||
- | |||
- | ==== DMPE ==== | ||
- | |||
- | //1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine// | ||
- | |||
- | | {{ mm:parameters:lipids:dmpe.png?70 }} | Name | //1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine// ||| | ||
- | | ::: | 4-Letter code | DMPE ||| | ||
- | | ::: | sn<sub>1</sub>-sn<sub>2</sub> | 14:0/14:0 ||| | ||
- | | ::: | parameters | {{ mm:parameters:lipids:dme_frcmod.zip | frcmod }} {{ mm:parameters:lipids:dme_prepc.zip | prepc }} || [[#references | [Coimbra, 2013]]] | | ||
- | | ::: | **Validation** |||| | ||
- | | ::: | //Value// | //MD ± σ / Å// ||| | ||
- | | ::: | //V<sub>L</sub>// | 961 ± 2 ||| | ||
- | | ::: | //A<sub>L</sub>// | 44 ± 0.7 ||| | ||
- | | ::: | //D<sub>HH</sub>// | 42 ± 0.1 ||| | ||
- | |||
- | |||
- | ==== DPPE ==== | ||
- | |||
- | //1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine// | ||
- | |||
- | | {{ mm:parameters:lipids:dppe.png?70 }} | Name | //1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine// ||| | ||
- | | ::: | 4-Letter code | DPPE ||| | ||
- | | ::: | sn<sub>1</sub>-sn<sub>2</sub> | 16:0/16:0 ||| | ||
- | | ::: | parameters | {{ mm:parameters:lipids:dpe_frcmod.zip | frcmod }} {{ mm:parameters:lipids:dpe_prepc.zip | prepc }} || [[#references | [Coimbra, 2013]]] | | ||
- | | ::: | **Validation** |||| | ||
- | | ::: | //Value// | //MD ± σ / Å// ||| | ||
- | | ::: | //V<sub>L</sub>// | 1066 ± 3 ||| | ||
- | | ::: | //A<sub>L</sub>// | 44 ± 0.5 ||| | ||
- | | ::: | //D<sub>HH</sub>// | 47 ± 0.3 ||| | ||
- | |||
- | ==== DSPE ==== | ||
- | |||
- | //1,2-distearoyl-sn-glycero-3-phosphoethanolamine// | ||
- | |||
- | | {{ mm:parameters:lipids:dspe.png?65 }} | Name | //1,2-distearoyl-sn-glycero-3-phosphoethanolamine// ||| | ||
- | | ::: | 4-Letter code | DSPE ||| | ||
- | | ::: | sn<sub>1</sub>-sn<sub>2</sub> | 18:0/18:0 ||| | ||
- | | ::: | parameters | {{ mm:parameters:lipids:dse_frcmod.zip | frcmod }} {{ mm:parameters:lipids:dse_prepc.zip | prepc }} || [[#references | [Coimbra, 2013]]] | | ||
- | | ::: | **Validation** |||| | ||
- | | ::: | //Value// | //MD ± σ / Å// ||| | ||
- | | ::: | //V<sub>L</sub>// | 1162 ± 3 ||| | ||
- | | ::: | //A<sub>L</sub>// | 43 ± 0.3 ||| | ||
- | | ::: | //D<sub>HH</sub>// | 52 ± 0.2 ||| | ||
- | |||
- | ==== POPE ==== | ||
- | |||
- | //1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine// | ||
- | |||
- | | {{ mm:parameters:lipids:pope.png?65 }} | Name | //1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine// ||| | ||
- | | ::: | 4-Letter code | POPE ||| | ||
- | | ::: | sn<sub>1</sub>-sn<sub>2</sub> | 16:0/18:1(Δ<sup>9</sup>) ||| | ||
- | | ::: | parameters | {{ mm:parameters:lipids:poe_frcmod.zip | frcmod }} {{ mm:parameters:lipids:poe_prepc.zip | prepc }} || [[#references | [Coimbra, 2013]]] | | ||
- | | ::: | **Validation** |||| | ||
- | | ::: | //Value// | //MD ± σ / Å// | //Experimental / Å// | //Reference// | | ||
- | | ::: | //V<sub>L</sub>// | 1149 ± 3 | 1185 | [[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1302872/|Rappolt, 2003]] | | ||
- | | ::: | //A<sub>L</sub>// | 46 ± 0.6 | 61.0 | ::: | | ||
- | | ::: | //D<sub>HH</sub>// | 48 ± 0.3 | 39.0 | ::: | | ||
- | |||
- | ==== PLPE ==== | ||
- | |||
- | //1-palmitoyl-2-linoleoyl-sn-glycero-phosphoethanolamine// | ||
- | |||
- | | {{ mm:parameters:lipids:plpe.png?65 }} | Name | //1-palmitoyl-2-linoleoyl-sn-glycero-phosphoethanolamine// || | ||
- | | ::: | 4-Letter code | PLPE || | ||
- | | ::: | sn<sub>1</sub>-sn<sub>2</sub> | 16:0/18:2(Δ<sup>9,12</sup>) || | ||
- | | ::: | parameters | {{ mm:parameters:lipids:ple_frcmod.zip | frcmod }} {{ mm:parameters:lipids:ple_prepc.zip | prepc }} | [[#references | [Coimbra, 2013]]] | | ||
- | | ::: | **Validation** ||| | ||
- | | ::: | //Value// | //MD ± σ / Å// || | ||
- | | ::: | //V<sub>L</sub>// | 1152 ± 2 || | ||
- | | ::: | //A<sub>L</sub>// | 48 ± 0.5 || | ||
- | | ::: | //D<sub>HH</sub>// | 46 ± 0.3 || | ||
- | |||
- | ===== References ===== | ||
- | |||
- | Coimbra, J.T.S.; Sousa, S.F.; Fernandes, P.A.; Rangel, M.; Ramos, M.J.. [[http://www.tandfonline.com/doi/abs/10.1080/07391102.2012.750250?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed#.UfAXYY1wrt4 | Biomembrane simulations of 12 lipid types using the general amber force field in a tensionless | ||
- | ensemble]] . //J. Biomol. Struct. Dyn.//, **2013** |